Sunday, August 16, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
InjectablesHugel Posts Record H1 on Toxin Surge—Overseas Growth AcceleratestodayMarketHugel Posts Record H1 Revenue on Overseas Toxin Surge3 days agoDevices & TechApyx: GLP-1 Boom Is Fueling Renuvion DemandtodayMarketMedytox Q2 Sales Up 11%, Operating Profit Down 25%3 days agoInjectablesGalderma Wins EU Nod for Restylane ShaypeyesterdayBusiness & M&AEstablishment Labs Raises 2026 Revenue Guidance2 days agoDevices & TechMerz Ultherapy PRIME Clears FDA for Knee Skin LaxityyesterdayBusiness & M&ABeauty Health Q2 Earnings: Device Demand Steady2 days agoInjectablesHugel Debuts Thechaum Signature with Reduced CrosslinkeryesterdayDevices & TechAlma Launches TitaniumLift™ Multi-Depth RF Protocol2 days agoInjectablesGLP-1 Boom Exposed Filler Limitations—Here's WhyyesterdayInjectablesGalderma Chief: Start GLP-1 Patients on Skin Care First2 days ago
Trade & Tariffs

Entity List

A Commerce Department blacklist barring U.S. firms from supplying named foreign companies without a license.

Also known as: BIS Entity List

What it is
The Entity List is a Commerce Department roster of foreign parties subject to license requirements for receiving U.S.-origin items. Being listed sharply restricts what American suppliers can sell to them. Licenses are often presumptively denied.
What it does
Adding a major foreign customer to the list can eliminate a revenue stream for U.S. suppliers overnight, while sometimes benefiting non-U.S. competitors. Investors map supplier exposure to newly listed entities. It is a precise, single-target catalyst.
The evidence
Placing large foreign technology firms on the Entity List has forced U.S. suppliers to halt shipments and disclose revenue impacts.
Best for
Chip and component suppliers exposed to listed customers; varies by disclosure.
Pairs well with
export-controls, sanctions, section-301
Use cautiously with
Temporary general licenses and workarounds can soften the blow; assuming an instant total cutoff overstates near-term impact.
Cautions
Exposure is often undisclosed at the customer level, so estimates carry uncertainty.
General information, not medical advice. Ingredient effects vary by formulation, concentration, and skin. Patch-test new actives and consult a qualified provider before starting prescription ingredients.

Know what's coming before your patients ask for it.

New actives, device launches, and the FDA calls that change what you can offer — distilled into a two-minute brief, twice a week. Inside MedSpa Pro.

Go Pro · $20/mo
Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
The twice-a-week intelligence brief Go Pro · $20/mo